Study of Olutasidenib and Temozolomide in HGG

Clinical trial NCT06161974 · RECRUITING

Trial details

NCT number: NCT06161974
Sponsor: Rigel Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High Grade Glioma Astrocytoma Astrocytoma, Grade III Astrocytoma, Grade IV Diffuse Intrinsic Pontine Glioma WHO Grade III Glioma WHO Grade IV Glioma Metastatic Brain Tumor Diffuse Midline Glioma, H3 K27M-Mutant Thalamus Tumor Spinal Tumor IDH1 Mutation

Start date: 2025-02-01
Primary completion: 2029-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.